Unlocking the Potential of Allogeneic Vδ2 T Cells for Ovarian Cancer Therapy through CD16 Biomarker Selection and CAR/IL-15 Engineering

By employing CD16 as a donor selection biomarker, investigators harnessed Vδ2 T cells characterized by heightened cytotoxicity and potent antibody-dependent cell-mediated cytotoxicity functionality.